
Creating a New Class of Drugs to Address Incurable Autoimmune Diseases

Entelexo Biotherapeutics is focused on developing innovative therapeutic solutions utilizing engineered exosomes. Their proprietary engineering platform allows for the creation of a new class of exosome-based therapeutics specifically designed to address the complexities associated with autoimmune diseases. These diseases, including Rheumatoid Arthritis, Crohn’s Disease, and Psoriasis, currently have no cure and are often treated with a one-size-fits-all approach that targets a single cytokine. Entelexo aims to overcome this limitation by leveraging exosomes to communicate with multiple and sp…